Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

BMS and BioNTech partner on solid tumour candidate in deal worth over $11bn

BioNTech’s BNT327 is being evaluated in multiple clinical trials, including phase 3 studies in first-line lung cancer

- PMLiVE

AstraZeneca’s Forxiga recommended by NICE for wider chronic kidney disease use

An estimated 7.2 million people in the UK are living with the progressive condition

- PMLiVE

Roche/Jazz share positive phase 3 results for lung cancer combination therapy

Approximately 30,000 new cases of small cell lung cancer are reported in the US every year

- PMLiVE

Focusing on the patient voice to improve outcomes

By Tamara Ghanem

- PMLiVE

How can we achieve the right balance of HCP engagements in medcomms?

By Janisha Ladva and Laura Wilson

- PMLiVE

Pfizer shares ‘unprecedented’ survival results for Braftovi in colorectal cancer

Around 154,270 people are expected to be diagnosed with cancer of the colon or rectum in the US this year

- PMLiVE

Sanofi to expand immunology capabilities with $9.5bn Blueprint acquisition

The deal will grant Sanofi access to a drug approved for the rare immunologic disorder systemic mastocytosis

- PMLiVE

Eli Lilly’s Omvoh recommended by NICE to treat Crohn’s disease in adults

Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK

- PMLiVE

Between luck and leadership: success because of, not despite, strategy

By Chris Hall

- PMLiVE

The evolution of AI in clinical trials: from promise to practice

By David Kane

- PMLiVE

Medscape Online Continuing Medical Education Led to New Diagnoses in Alzheimer’s Disease

Medscape Education has recently published a study looking at the real-world impact of online continuing medical education on Alzheimer's disease diagnosis. Read the full article here.  The study, published in...

Medscape Education

- PMLiVE

Roche shares positive 96-week results for multiple sclerosis candidate fenebrutinib

The immune-mediated disease affects more than 2.9 million people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links